Standard usage, dosage and taking guidelines for brigatinib/brigatinib (Embry)

Brigatinib/Brigatinib (Brigatinib) is an oral second-generation ALK (anaplastic lymphoma kinase) inhibitor, mainly used for patients with ALK-positive non-small cell lung cancer (NSCLC). It is designed to overcome crizotinib resistance and provide precise treatment options for ALK mutations and their drug-resistant subtypes. Brigatinib inhibits tumor cell proliferation and metastasis by inhibiting the activity of ALK kinase and blocking downstream signaling pathways, and has shown good central nervous system efficacy in patients with brain metastases.

The regimen of brigatinib is divided into two phases: initial dose and maintenance dose. Adult patients usually take 90 mg daily during the first seven days of treatment to help the body gradually adapt to the drug and reduce the risk of adverse reactions. After entering the maintenance period, the dose is adjusted to 180 mg once a day, which is the clinically recommended standard dose. The drug is administered orally and can be taken with food or on an empty stomach, but it should be taken at a fixed time every day to maintain the stability of blood concentration and ensure sustained efficacy.

During the course of taking the medication, patients need to pay attention to their tolerance to the medication. If significant side effects occur, such as rash, nausea, abnormal liver function, or respiratory discomfort, your doctor may adjust the dose or temporarily discontinue the drug based on the specific situation. In addition, brigatinib has a variety of drug interactions, especially when used concurrently with CYP3A4 inhibitors or inducers, which may affect plasma concentrations. Patients should inform their doctors in detail about all prescription drugs, over-the-counter drugs and supplements they are taking before taking them to avoid potential risks.

Long-term use of brigatinib also requires attention to indicators such as heart, electrolyte and liver function. Regular blood routine, liver and kidney function and electrocardiogram follow-up are necessary in order to detect potential toxic reactions and intervene in time. Clinical practice shows that patients who follow the recommended dosage and follow-up strategies can maximize the anti-tumor efficacy of brigatinib while reducing the impact of side effects on quality of life.

Reference materials:https://www.alunbrig.com/